Unravelling the predictors of late cancer presentation and diagnosis in Jordan: a cross-sectional study of patients with lung and colorectal cancers.
Gastrointestinal tumours
PREVENTIVE MEDICINE
PUBLIC HEALTH
Quality in health care
Respiratory tract tumours
Journal
BMJ open
ISSN: 2044-6055
Titre abrégé: BMJ Open
Pays: England
ID NLM: 101552874
Informations de publication
Date de publication:
02 05 2023
02 05 2023
Historique:
medline:
4
5
2023
pubmed:
3
5
2023
entrez:
2
5
2023
Statut:
epublish
Résumé
Late presentation or diagnosis of cancer results in a poor clinical prognosis, negatively affects treatment and subsequently lowers one's chances of survival. This study aimed to identify the factors associated with late lung and colorectal cancer presentation and diagnosis in Jordan. This correlational cross-sectional study was based on face-to-face interviews and medical chart reviews from a cancer registry database. A structured questionnaire based on a review of the literature was used. The study participants were a representative sample of adult patients with colorectal or lung cancer who visited the outpatient clinics at King Hussein Cancer Center in Amman, Jordan, between January 2019 and December 2020, to get their first medical consultation. 382 study participants were surveyed, with a response rate of 82.3%. Of these, 162 (42.2%) reported a late presentation and 92 (24.1%) reported a late diagnosis of cancer. The results of backward multivariate logistic regression analyses showed that female gender and not seeking a medical advice when feeling ill combined was associated with an almost three times increased likelihood of reporting a late presentation with cancer (adjusted OR 2.97, 95% CI 1.19 to 7.43). Not having health insurance and not seeking medical advice combined was also associated with late presentation (2.5, 95% CI 1.02 to 6.12). For lung cancer, Jordanians living in rural areas were 9.29 (95% CI 2.46 to 35.1) times more likely to report late diagnosis. Jordanians who did not screen for cancer in the past were 7.02 (95% CI 1.69 to 29.18) times more likely to report late diagnosis. For colorectal cancer, those having no previous knowledge about cancers or screening programmes had increased odds of reporting late diagnosis (2.30, 95% CI 1.06 to 4.97). This study highlights important factors associated with the late presentation and diagnosis of colorectal and lung cancers in Jordan. Investing in national screening and early detection programmes as well as public outreach and awareness campaigns will have a significant impact on early detection to improve treatment outcomes.
Identifiants
pubmed: 37130680
pii: bmjopen-2022-069529
doi: 10.1136/bmjopen-2022-069529
pmc: PMC10163555
doi:
Types de publication
Review
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e069529Informations de copyright
© Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: None declared.
Références
Br J Cancer. 2006 May 8;94(9):1272-80
pubmed: 16622459
Qual Life Res. 2021 Feb;30(2):315-343
pubmed: 32948975
Eur J Oncol Nurs. 2020 Feb;44:101677
pubmed: 31751849
J Family Med Prim Care. 2020 May 31;9(5):2214-2218
pubmed: 32754476
Public Health Rep. 2014 Jan-Feb;129 Suppl 2:19-31
pubmed: 24385661
Br J Cancer. 2016 Aug 23;115(5):533-41
pubmed: 27490803
J Gastrointest Cancer. 2016 Mar;47(1):36-46
pubmed: 26615546
J Gen Intern Med. 2018 Dec;33(12):2100-2105
pubmed: 30284171
PLoS One. 2022 Jan 13;17(1):e0262468
pubmed: 35025941
BMC Health Serv Res. 2017 Jun 28;17(1):448
pubmed: 28659143
Rev Esp Enferm Dig. 2011 Sep;103(9):458-63
pubmed: 21951114
BMJ Open. 2020 Apr 22;10(4):e034351
pubmed: 32327476
Br J Cancer. 2009 Dec 3;101 Suppl 2:S92-S101
pubmed: 19956172
Med J Malaysia. 2015 Jun;70(3):148-52
pubmed: 26248776
J Cancer Epidemiol. 2018 Oct 17;2018:2937067
pubmed: 30416523
Annu Rev Public Health. 2018 Apr 1;39:273-289
pubmed: 29328865
PLOS Glob Public Health. 2022 Jan 4;2(1):e0000149
pubmed: 36962139
JCO Glob Oncol. 2020 Feb;6:260-268
pubmed: 32083950
Asian Pac J Cancer Prev. 2013;14(2):1141-5
pubmed: 23621202
Crit Rev Oncol Hematol. 2019 Apr;136:20-30
pubmed: 30878125
JAMA Netw Open. 2021 Apr 1;4(4):e214708
pubmed: 33825840
Ann Surg Oncol. 2015 Mar;22(3):883-8
pubmed: 25212834
Fam Pract. 2013 Aug;30(4):436-44
pubmed: 23377608
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Breast J. 2016 Mar-Apr;22(2):213-7
pubmed: 26661458
J Ayub Med Coll Abbottabad. 2018 Oct-Dec;30(4):558-561
pubmed: 30632337
BMC Cancer. 2015 Dec 23;15:1000
pubmed: 26698112
Asian Pac J Cancer Prev. 2019 Aug 01;20(8):2339-2343
pubmed: 31450904
Expert Rev Pharmacoecon Outcomes Res. 2021 Aug;21(4):647-654
pubmed: 33353434
Cancer Res Treat. 2019 Jul;51(3):1098-1106
pubmed: 30428639
Sci Rep. 2020 Dec 8;10(1):21477
pubmed: 33293634
Br J Cancer. 2008 Jan 15;98(1):60-70
pubmed: 18059401
PLoS One. 2019 Mar 5;14(3):e0213362
pubmed: 30835777
Curr Oncol. 2017 Dec;24(6):367-373
pubmed: 29270048
BMC Res Notes. 2012 Aug 21;5:452
pubmed: 22909280
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
Cold Spring Harb Perspect Med. 2021 Sep 1;11(9):
pubmed: 34001525
Public Health. 2016 Sep;138:50-6
pubmed: 27091437
Prim Health Care Res Dev. 2015 Nov;16(6):618-22
pubmed: 25660904
AMA J Ethics. 2020 Feb 1;22(2):E147-155
pubmed: 32048585
Br J Cancer. 2011 Apr 12;104(8):1249-55
pubmed: 21487428